Alto Neuroscience, Inc. ANRO
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 27.99M | 23.35M | 21.89M | 20.75M | 21.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 100.55M | 88.27M | 77.83M | 66.36M | 66.31M |
| Operating Income | -100.55M | -88.27M | -77.83M | -66.36M | -66.31M |
| Income Before Tax | -95.18M | -84.24M | -74.31M | -63.24M | -62.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -95.18 | -84.24 | -74.31 | -63.24 | -62.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -95.18M | -84.24M | -74.31M | -63.24M | -62.26M |
| EBIT | -100.55M | -88.27M | -77.83M | -66.36M | -66.31M |
| EBITDA | -99.84M | -87.58M | -77.15M | -65.70M | -65.63M |
| EPS Basic | -2.46 | -2.44 | -2.45 | -2.21 | -2.31 |
| Normalized Basic EPS | -1.54 | -1.52 | -1.53 | -1.37 | -1.43 |
| EPS Diluted | -2.46 | -2.44 | -2.45 | -2.21 | -2.31 |
| Normalized Diluted EPS | -1.54 | -1.52 | -1.53 | -1.37 | -1.43 |
| Average Basic Shares Outstanding | 156.42M | 136.99M | 121.25M | 115.41M | 108.00M |
| Average Diluted Shares Outstanding | 156.42M | 136.99M | 121.25M | 115.41M | 108.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |